Empagliflozin and Elderly Patients With Preserved Ejection Fraction Heart Failure: Is Age Just a Number?
- PMID: 35772912
- DOI: 10.1016/j.jacc.2022.04.037
Empagliflozin and Elderly Patients With Preserved Ejection Fraction Heart Failure: Is Age Just a Number?
Keywords: age; cardiovascular outcomes; empagliflozin; heart failure; kidney function.
Conflict of interest statement
Funding Support and Author Disclosures Dr Sauer has received research funding support from Boehringer Ingelheim as a site principal investigator enrolling patients in the EMPEROR-Preserved trial; he no longer receives funding because the trial has closed and he has not consulted for the company.
Comment on
-
Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age.J Am Coll Cardiol. 2022 Jul 5;80(1):1-18. doi: 10.1016/j.jacc.2022.04.040. J Am Coll Cardiol. 2022. PMID: 35772911 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
